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The Fibrinolytic Therapy Trialists’ (1) overview of 58,600
patients randomized to receive either fibrinolytic or control
treatment reported a 23% mortality reduction with fibrinolytic
therapy among patients who presented with myocardial infarc-
tion with ST segment elevation and were randomized within
6 h of symptom onset. These data are compelling, and it is no
longer ethical to withhold fibrinolytic therapy from patients
with these demographics. The mortality rate in the Global
Utilization of Streptokinase and TPA [tissue plasminogen
activator] for Occluded Coronary Arteries (GUSTO-I) trial
was 6.3% with aspirin, tissue-type plasminogen activator (t-
PA) and intravenous heparin. The intracranial hemorrhage
rate was 0.72%, and the total stroke rate was 1.55%. These
figures are too high, and would not be accepted in other areas
of medicine. More effective thrombolytic regimens are there-
fore required, and these new regimens will preferably be safer,
more easily administered or cheaper. It is therefore incumbent
on cardiologists to continue to explore ways of improving
patient outcomes after myocardial infarction and to test these
in appropriately designed trials—but how can this be done if it
is unethical to use placebo-controlled trials? In this issue of the
Journal, Tebbe et al. (2) use an equivalence design to test
whether saruplase was “equivalent” to streptokinase in a
randomized trial of 3,081 patients.
Saruplase is unglycosylated single-chain urokinase-type
plasminogen activator, produced by genetically transformed
Escherichia coli. It is converted into active two-chain
urokinase-type plasminogen activator by plasmin, and it also
activates plasminogen directly, largely in the presence of fibrin.
Saruplase has been associated with high patency rates in
angiographic studies (3) and may be cheaper than other
currently available fibrin-specific thrombolytic agents. This
trial is much smaller than the Gruppo Italiano per lo Studio
della Sopravvivenza nell’Infarto Miocardico (GISSI-2) trial,
the Third International Study of Infarct Survival (ISIS-3) or
the GUSTO-I trial, which together randomized between
20,000 and 40,000 patients to detect whether t-PA was superior
to streptokinase. In this commentary, the trial design and
interpretation and issues of superiority, equivalence and suffi-
ciency trials are discussed.
The mechanism of benefit of thrombolytic therapy is the
opening of occluded infarct-related arteries (4). Maximal
benefit is obtained when reperfusion is achieved early and flow
in the infarct-related artery is brisk and sustained. Is it
appropriate to assume that this paradigm will translate into a
mortality reduction if a new agent is shown to achieve greater
rates of Thrombolysis in Myocardial Infarction (TIMI) grade 3
flow (5) or a lower corrected TIMI frame count (6) than an
established agent, thus avoiding the need for megatrials?
Two recent, large megatrials evaluating mortality outcomes
have not confirmed the promising findings of pilot patency
trials. TIMI grade 3 flow with t-PA was reported to be 88%
when given as a double bolus (7) compared with 54% when
administered over 90 min in the GUSTO-I trial (8). However,
the Continuous Infusion Versus Double-Bolus Administration
of Alteplase (COBALT) trial (9) in 7,169 patients showed that
double-bolus t-PA was “equivalent” to t-PA in its effects on
mortality. In the Reteplase Angiographic Phase II Interna-
tional Dose-Finding (RAPID-I and RAPID-II) trials, which
were the pilot studies for the Global Use of Strategies to Open
Occluded Coronary Arteries (GUSTO-III) trial, reteplase was
shown to be superior to t-PA in achieving 90-min TIMI grade
3 flow (reteplase 63% vs. accelerated t-PA 49%, p , 0.05)
(10,11). In the GUSTO-III trial, which enrolled 15,059 pa-
tients, reteplase was judged not to be superior to t-PA (12).
Thus, angiographic patency at 90 min is not necessarily a
perfect surrogate for mortality benefit and clearly cannot
predict intracranial hemorrhage rates with new thrombolytic
regimens. Larger trials are required to define benefit and risk.
The COBALT and GUSTO-III trials had different aims.
GUSTO-III used the reference standard in clinical research
(i.e., a double-blind, placebo-controlled design) with the hy-
pothesis that reteplase was superior to t-PA, and the statistical
testing was done to reject the null hypothesis of no treatment
difference. The COBALT trial was designed as a positive-
control “equivalence” trial, which aimed to demonstrate the
therapeutic equivalence of double-bolus administration and
accelerated administration of t-PA by testing the null hypoth-
esis that the absolute mortality difference at 30 days would be
.0.4% with double-bolus t-PA. This value is the lower 95%
confidence limit of the 1% mortality difference between t-PA
and streptokinase shown in GUSTO-I (8). If this boundary was
not exceeded, superiority of double-bolus t-PA over streptoki-
nase would have been claimed. This design is methodologically
very different from a “null-control” trial.
In equivalence trials the new thrombolytic agent should be
proved superior to control (i.e., nonthrombolytic) treatment,
and these trials generally need to be larger than superiority
trials, not smaller (13). Given the streptokinase mortality rate
of 6.7% in the current trial, it would take 10,000 patients to
show a 20% superiority of saruplase with a power of 80% and
p , 0.05. The current trial has only a 32% power to show a
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20% superiority. Failure to detect a difference in a statistically
underpowered superiority trial does not prove equivalence,
and “lack of evidence of difference” is not the same as
“evidence of a lack of difference.” The current trial was
designed to exclude a mortality increase of 50% with saruplase
over streptokinase and to claim equivalence if the difference in
mortality was ,50%.
The choice of a prespecified absolute difference to define
equivalence has been used in other trials (9,14). This approach
increases the chance of showing equivalence if a low risk
population is studied. For example, it would be much more
difficult to show a 1% absolute difference between a new agent
and t-PA if the baseline mortality were 5% than if the baseline
mortality were 10%. In the present trial, the mortality rate at
30 days was 6.7% in patients randomized to receive streptoki-
nase, which compares with a mortality rate of 12% in previous
streptokinase versus control trials (15–20) and a 42% higher
mortality of 9.5% in the International Joint Efficacy Compar-
ison of Thrombolytic’s (INJECT) trial (14), a previous equiv-
alence trial of reteplase versus streptokinase.
Rather than using absolute reductions, the preferred ap-
proach may be to use a prespecified percentage or odds
reduction for limits of the range of equivalence, as in the
current trial, in which a prespecified odds ratio of 1.5 was
chosen. According to this definition, if the 95% confidence
limits do not overlap this boundary, the new treatment can be
regarded as equivalent (13) (Fig. 1).
Six previous trials of streptokinase versus control treatment
in patients randomized with ST segment elevation within 6 h of
symptom onset showed a 24% reduction in mortality (odds
ratio 0.76, 95% confidence interval 18% to 31%) (15–20). If
exclusion of an 18% increase in mortality with saruplase over
streptokinase had been chosen in the current trial (i.e., to
exclude overlapping the lower boundary of the confidence
interval), the statistical power would have been only 23%.
Figure 2 depicts the results of the current trial, which shows
a 16% mortality reduction with saruplase versus streptokinase,
with an upper 95% confidence limit of 1.09 (i.e., there could be
a 9% increase in mortality with saruplase) not overlapping the
confidence limits of the previous streptokinase versus control
trials. Saruplase has therefore been shown to be equivalent to
streptokinase, but not superior. It would also have been
informative to explore the consistency of this effect across
subgroups, such as the elderly, patients with anterior infarc-
tion, patients presenting before and after 6 h and those actually
receiving the treatments.
It is very important that a population similar to that in the
previous streptokinase versus control trials be used if assump-
tions are to be made about superiority to control treatment.
Age is the most important adverse prognostic factor for
mortality and stroke (21), and it is surprising that the first 800
patients enrolled in the current study excluded those .75 years
old. One cannot therefore confidently apply the trial results to
elderly patients, in whom streptokinase may be preferred
because of its lower rate of intracranial hemorrhage.
There were also imbalances between the patients random-
Abbreviations and Acronyms
COBALT 5 Continuous Infusion Versus Double-Bolus
Administration of Alteplase
GUSTO-I 5 Global Utilization of Streptokinase and TPA for
Occluded Coronary Arteries
GUSTO-III 5 Global Use of Strategies to Open Occluded Coronary
Arteries
TIMI 5 Thrombolysis in Myocardial Infarction
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Figure 1. Equivalence testing with a range of equiva-
lence and statistical significance. Horizontal lines 5
95% confidence intervals; dashed vertical lines 5 limits
of the range of equivalence. 2ve 5 negative; 1ve 5
positive. Modified, with permission, from Jones et al.
(13).
Figure 2. Comparison of streptokinase versus placebo from previous
randomized, controlled trials showing a 24% reduction in mortality at
30 days with streptokinase (95% confidence interval 18% to 31%) and
comparison of saruplase versus streptokinase showing a 16% mortality
reduction (95% confidence interval 237% to 9%). The confidence
limits do not overlap, therefore showing equivalence.
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ized to receive saruplase and those randomized to receive
streptokinase. The two significant imbalances would count
against streptokinase. Patients who received streptokinase
were, on average, 1.1 years older than those who received
saruplase, and 4.2% more patients in the saruplase group were
current smokers, who have been shown to have a lower 30-day
mortality rate than that of nonsmokers or ex-smokers (22).
When comparing a new thrombolytic agent with an estab-
lished agent it is necessary to show that the new agent is
“clinically” indistinguishable from the old agent (i.e., similar
enough to be clinically accepted as equivalent). This type of
trial has been termed a “sufficiency trial.” Do the results of the
current trial enable us to declare that saruplase and streptoki-
nase are clinically similar? The investigators of the saruplase
trial provide supportive, but not compelling, evidence that
saruplase is a suitable alternative to streptokinase. The intra-
cranial hemorrhage rates were 0.9% and 0.3% for saruplase
and streptokinase, respectively (p , 0.05). The 95% confi-
dence interval includes an absolute increase of 0.3% to 1.4% in
intracranial hemorrhage with saruplase. However, the num-
bers of patients with total stroke and nonfatal disabling strokes
were similar, but again the confidence intervals are wide, with
the possibility of a 0.8% reduction in stroke or a 0.9% absolute
increase with saruplase.
Conclusions. There are three approaches for improving on
the current thrombolytic regimens. The first is to attempt to
improve on nature with a more effective mutant or chimeric of
native t-PA. To date this improvement has not been achieved.
The drugs being tested in current megatrials—lanoteplase and
TNK–t-PA—have several features with the potential to im-
prove patient care. However, in small trials without the power
to draw definitive conclusions, the stroke rates with these
agents have been similar to those with t-PA, which was
associated with a stroke rate of 1.83% in the GUSTO-III trial.
A second approach is to reduce the dose of the thrombolytic
agent and add a glycoprotein IIb/IIIa receptor antagonist. A
third approach is to add an adjunctive therapy, such as hirulog,
to streptokinase, the aim being to improve patient outcome by
improving infarct-related artery patency without increasing the
stroke rate (22). All three approaches are presently being
evaluated in equivalence or superiority trials that will total
.50,000 patients worldwide, including areas of Eastern Eu-
rope, Latin America and Asia that have not previously partic-
ipated in large cardiologic trials. The collaboration and enthu-
siasm of the investigators is impressive, and it is hoped that this
research will improve patient care.
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